Jorge Manzanares Robles graduated in Pharmacy at the Complutense University of Madrid in 1985. He received his Ph.D. in Pharmacology at the Department of Pharmacology of the Faculty of Pharmacy of the Complutense University in 1987. During this predoctoral phase, he also worked in the Research Service and the Psychiatry Service of the Ramón y Cajal Hospital in Madrid and the Biochemistry Service of the La Paz Hospital in Madrid.
From 1988 to 1993, he was hired as a Research Associate by the Department of Pharmacology and Toxicology of the Michigan State University in East Lansing, Michigan, USA. Upon his return to Spain, he worked as a researcher contracted by the Ministry of Education in the Departments of Pharmacology of the Faculty of Pharmacy and Biochemistry and Molecular Biology of the Faculty of Medicine of the Complutense University, in the Neuropathology Unit of the Ramón y Cajal Neurobiology Institute of Madrid of the Higher Council for Scientific Research and the Brain Mapping Unit of the Multidisciplinary Institute of the Complutense University of Madrid, and as a Contract Researcher for the Ministry of Health in the Psychiatry Service and Research Unit of the Hospital 12 de Octubre in Madrid. In November 2004, he obtained by competitive examination (civil servant) the position of Professor in the Area of Pharmacology at the University Miguel Hernández of Alicante (UMH), where he teaches the subject of Pharmacology in the degrees of Pharmacy and Medicine. Since May 2011, he has been a Professor of Pharmacology and since June of the same year Dean of the Faculty of Pharmacy at the University Miguel Hernández in the campus of San Juan de Alicante. Since November 2004, he has been a member of the Institute of Neurosciences of Alicante, a joint UMH-Superior Council for Scientific Research, where he directs the Translational Neuropsychopharmacology laboratory. From November 2007 to October 2011, through a collaboration agreement FISCAM-Universidad Miguel Hernández, he was the promoter and Director of the Translational Neuropsychopharmacology Unit at the Albacete University Hospital Complex, in Castilla-La Mancha. From October 2008 to October 2010, he was the Scientific Director of the “Chair for training and research in Parkinson’s disease” based at the Neurosciences Institute of the Miguel Hernández University and funded by DISTEC. In June 2013, he was appointed Vocal for Spain of the Ibero-American Conference of Faculties of Pharmacy and renewed in the next elections up to date. In August 2014, he was appointed “Adjunct Professor” of the Department of Psychiatry at the “New York University” (NYU) in New York City in the United States. In February 2015, he was appointed “Honorary Professor” at the Norbert Wiener Private University of Lima (Peru). Since October 2015, he has been the Director of the Official Master in Translational Neuropsychopharmacology at Miguel Hernández University. Since April 2016, he has been part of the Executive Committee of the Spanish Society of Dual Pathology as Vocal of Basic Research. In September of the same year, he was appointed External Advisor for the Harmonization of Pharmacy and Biochemistry Studies by the Academic Authorities, Representatives, and delegates of the Faculties and Careers of Pharmacy and Biochemistry of the Bolivian Public Universities. In 2018 he was elected Corresponding Academician of the Academy of Pharmacy Santa Maria de Murcia, Corresponding Academician of the Iberoamerican Academy of Pharmacy, and Senior Professor and Consulting Researcher of the Faculty of Medicine of the University of Cartagena de Indias in Colombia. In 2019 he was appointed Full Academician (medal 49) of the Royal National Academy of Pharmacy of Spain of the Institute of Spain, Foreign Corresponding Academician of the National Academy of Pharmaceutical Sciences of Mexico, and Corresponding Academician of the Mexican Academy of Psychiatry and Mental Health. In 2021, he received the title of “Distinguished Visitor” by the Faculty of Chemical Sciences of the University of Cordoba (Argentina). Also, in this same year, he received the “2021 APS Outstanding Contribution Award” for the article “Cannabidiol does not display drug abuse potential in mice behavior.” Dr. Manzanares has been the principal investigator of more than 50 research projects on animal modeling and clinical studies funded by public funds (Ministry of Education and Science, Ministry of Health, Autonomous Communities) and private funds (La Caixa Foundation, Biomedical Foundation of Mutua Madrileña, Brain and Mind Foundation, Neurosciences and Aging Foundation and various pharmaceutical companies). 2014, 2015, 2016, 2016, 2017, 2018, and 2019 Award for Research Performance by Professors of the Miguel Hernández University. 2016 Award of the Iberoamerican Academy of Pharmacy.
Dr. Manzanares has published more than 200 scientific articles in international journals and book chapters on different aspects of neuropsychopharmacology of neuropsychiatric diseases. He has a H=48 index with more than 6,700 citations. He has presented 280 communications to national and international congresses. He has been invited to give more than 300 scientific conferences in Spain, the United Kingdom, France, Netherlands, Sweden, Switzerland, Germany, Malta, Portugal, Russia, Belgium, Italy, Canada, United States, Argentina, Costa Rica, Colombia, Mexico, Bolivia, Cuba, Ecuador, Panama, Peru, and Brazil. He has coordinated 60 sessions in national and international congresses in the last ten years. Since 1997 he has been Project Evaluator of the National Agency for Evaluation and Prospective, Pharmacology Area. Since 2000 he has been a Member of the Technical Evaluation Commission of the Health Research Fund, Carlos III Health Institute of the Ministry of Health. Since 2017 he has been Associate Editor of the section “Psychopharmacology” of the journal Frontiers in Psychiatry. Since 2020 he has been Associate Editor of the section “Mental health and addictive disorders” of the journal Exploration of Neuroprotective Therapy. Since 2021, he contributed as Associate Editor of Advances in Drug and Alcohol Research (ADAR) and International Journal of Molecular Sciences and two issues of Frontiers in Pharmacology. Since 2008, he has been part of the National Network of Addictive Disorders research group for excellence groups of the Spanish Ministry of Health. Since 2017 he has been the Director of the Biobank of the Network.